Published in J Control Release on October 27, 2006
HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev (2009) 2.13
Biological rationale for the design of polymeric anti-cancer nanomedicines. J Drug Target (2012) 0.93
Pharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released from colon-specific HPMA copolymer-9-AC conjugate in rats. Pharm Res (2007) 0.79
Antitumor efficacy of colon-specific HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenografts. Macromol Biosci (2009) 0.78
Design of smart HPMA copolymer-based nanomedicines. J Control Release (2015) 0.76
POLYMERIC BIOMATERIALS AND NANOMEDICINES. J Drug Deliv Sci Technol (2015) 0.76
Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res (1988) 3.26
DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science (1989) 2.11
Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res (1993) 1.88
Eukaryotic DNA topoisomerases I. Biochim Biophys Acta (1995) 1.76
Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res (2001) 1.56
Mechanism of the reaction catalyzed by the DNA untwisting enzyme: attachment of the enzyme to 3'-terminus of the nicked DNA. J Mol Biol (1978) 1.46
A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci (1992) 1.45
The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res (1992) 1.42
Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol (1997) 1.16
Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol (1998) 1.14
A new approach to the oral administration of insulin and other peptide drugs. Science (1986) 1.06
Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Drug Carrier Syst (1995) 1.04
Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins. J Control Release (2006) 1.00
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer (1997) 0.98
A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res (1995) 0.98
Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer (1994) 0.97
A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J Control Release (2005) 0.97
Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res (1992) 0.95
Use of azo polymers for colon-specific drug delivery. J Pharm Sci (1997) 0.92
Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol (1996) 0.91
Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release (2006) 0.90
Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. J Control Release (2005) 0.89
Why drugs fail: of mice and men revisited. Clin Cancer Res (2001) 0.89
Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res (1993) 0.89
Site-specific drug delivery in the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst (2000) 0.87
Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin. J Control Release (2001) 0.86
Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. J Med Chem (1987) 0.85
Pharmacokinetics of orally administered camptothecins. Ann N Y Acad Sci (2000) 0.84
Synthesis of bioadhesive lectin-HPMA copolymer-cyclosporin conjugates. Bioconjug Chem (2000) 0.83
Biorecognition of HPMA copolymer-lectin conjugates as an indicator of differentiation of cell-surface glycoproteins in development, maturation, and diseases of human and rodent gastrointestinal tissues. J Biomed Mater Res (2000) 0.83
Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int J Cancer (1993) 0.83
The colon as a possible target for orally administered peptide and protein drugs. Crit Rev Ther Drug Carrier Syst (2002) 0.83
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol (1998) 0.82
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. J Clin Oncol (1999) 0.82
Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. Clin Cancer Res (2003) 0.82
Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Appl (1994) 0.82
9-Aminocamptothecin and beyond. Preclinical and clinical studies. Ann N Y Acad Sci (1996) 0.81
Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. Eur J Pharm Sci (2006) 0.81
Plant antitumor agents. 22. Isolation of 11-hydroxycamptothecin from Camptotheca acuminata Decne: total synthesis and biological activity. J Med Chem (1986) 0.77
FURTHER FACTORS AFFECTING THE HYDROXYLATION OF ANILINE AND SOME OF ITS DERIVATIVES BY LIVER MICROSOMES. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1964) 0.76
Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev (2002) 2.27
HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev (2009) 2.13
Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev (2004) 1.55
Reversible hydrogels from self-assembling genetically engineered protein block copolymers. Biomacromolecules (2005) 1.35
PEGylation of poly(ethylene imine) affects stability of complexes with plasmid DNA under in vivo conditions in a dose-dependent manner after intravenous injection into mice. Bioconjug Chem (2005) 1.32
RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker alpha(v) beta3 integrin with MRT, mapping. Int J Nanomedicine (2007) 1.30
A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI. Bioconjug Chem (2008) 1.29
Refolding hydrogels self-assembled from N-(2-hydroxypropyl)methacrylamide graft copolymers by antiparallel coiled-coil formation. Biomacromolecules (2006) 1.28
Polymer chemistry: swell gels. Nature (2002) 1.26
Pharmacokinetics, biodistribution and contrast enhanced MR blood pool imaging of Gd-DTPA cystine copolymers and Gd-DTPA cystine diethyl ester copolymers in a rat model. Pharm Res (2006) 1.22
Bone-targeting macromolecular therapeutics. Adv Drug Deliv Rev (2005) 1.21
Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem (2003) 1.20
Intracellular processing of poly(ethylene imine)/ribozyme complexes can be observed in living cells by using confocal laser scanning microscopy and inhibitor experiments. Pharm Res (2002) 1.19
Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface. Angew Chem Int Ed Engl (2010) 1.17
Osteotropic Peptide that differentiates functional domains of the skeleton. Bioconjug Chem (2007) 1.17
Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One (2009) 1.15
The arthrotropism of macromolecules in adjuvant-induced arthritis rat model: a preliminary study. Pharm Res (2004) 1.14
Contrast-enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor-bearing mice. Magn Reson Med (2005) 1.14
Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential. Expert Opin Drug Deliv (2007) 1.14
Peptide-targeted Nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging. Biomacromolecules (2010) 1.12
Gadolinium-based contrast agents for magnetic resonance cancer imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 1.12
Biodegradable cystamine spacer facilitates the clearance of Gd(III) chelates in poly(glutamic acid) Gd-DO3A conjugates for contrast-enhanced MR imaging. Magn Reson Imaging (2006) 1.11
Hybrid hydrogels self-assembled from HPMA copolymers containing peptide grafts. Macromol Biosci (2006) 1.10
Pharmacokinetics and tissue retention of (Gd-DTPA)-cystamine copolymers, a biodegradable macromolecular magnetic resonance imaging contrast agent. Pharm Res (2005) 1.10
Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconjug Chem (2003) 1.08
Backbone degradable multiblock N-(2-hydroxypropyl)methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction. Biomacromolecules (2010) 1.08
Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. J Control Release (2003) 1.07
Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20. Bioconjug Chem (2009) 1.07
Effect of size and charge on pharmacokinetics and in vivo MRI contrast enhancement of biodegradable polydisulfide Gd(III) complexes. J Control Release (2006) 1.06
Water-soluble HPMA copolymer--prostaglandin E1 conjugates containing a cathepsin K sensitive spacer. J Drug Target (2006) 1.04
Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol Pharm (2006) 1.03
An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix. Mol Pharm (2010) 1.03
Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells. Bioconjug Chem (2003) 1.03
In Vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromolecular MRI contrast agent. Exp Biol Med (Maywood) (2007) 1.03
Synthesis, characterization, and gene delivery of poly-L-lysine octa(3-aminopropyl)silsesquioxane dendrimers: nanoglobular drug carriers with precisely defined molecular architectures. Mol Pharm (2007) 1.02
Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm Res (2002) 1.01
Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials (2009) 1.00
Integrin Targeted MR Imaging. Theranostics (2011) 1.00
Smart hydrogels containing adenylate kinase: translating substrate recognition into macroscopic motion. J Am Chem Soc (2008) 1.00
Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors. Biochemistry (2002) 0.99
Gadolinium-conjugated TiO2-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-weighted contrast enhancement in magnetic resonance images. Nanomedicine (2008) 0.99
PEG-g-poly(GdDTPA-co-L-cystine): effect of PEG chain length on in vivo contrast enhancement in MRI. Biomacromolecules (2005) 0.98
Dynamic light scattering study of self-assembly of HPMA hybrid graft copolymers. Biomacromolecules (2008) 0.98
Genetically engineered block copolymers: influence of the length and structure of the coiled-coil blocks on hydrogel self-assembly. Pharm Res (2007) 0.98
Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice. Mol Pharm (2009) 0.98
Subcellular trafficking of HPMA copolymer-Tat conjugates in human ovarian carcinoma cells. J Control Release (2003) 0.97
Endocytic uptake of a large array of HPMA copolymers: Elucidation into the dependence on the physicochemical characteristics. J Control Release (2010) 0.97
Synthesis and evaluation of globular Gd-DOTA-monoamide conjugates with precisely controlled nanosizes for magnetic resonance angiography. Biomacromolecules (2008) 0.97
Characterization of tumor angiogenesis with dynamic contrast-enhanced MRI and biodegradable macromolecular contrast agents in mice. Magn Reson Med (2008) 0.96
Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI. Biomaterials (2013) 0.96
Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol Pharm (2009) 0.95
PEG-g-poly(GdDTPA-co-L-cystine): a biodegradable macromolecular blood pool contrast agent for MR imaging. Bioconjug Chem (2004) 0.94
Novel polymerizable surfactants with pH-sensitive amphiphilicity and cell membrane disruption for efficient siRNA delivery. Bioconjug Chem (2007) 0.94
Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agents. Magn Reson Imaging (2008) 0.93
Stability in plasmas of various species of HPMA copolymer-PGE1 conjugates. Pharm Res (2007) 0.93
Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer. Bioconjug Chem (2012) 0.93
A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery. J Control Release (2008) 0.92
Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells. Mol Pharm (2008) 0.92
Self-association properties of HPMA copolymers containing an amphipathic heptapeptide. J Drug Target (2007) 0.92
Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers. Mol Pharm (2010) 0.92
Noninvasive visualization of pharmacokinetics, biodistribution and tumor targeting of poly[N-(2-hydroxypropyl)methacrylamide] in mice using contrast enhanced MRI. Pharm Res (2007) 0.92
Self-assembled hydrogels from poly[N-(2-hydroxypropyl)methacrylamide] grafted with beta-sheet peptides. Biomacromolecules (2009) 0.92
Tumor characterization with dynamic contrast enhanced magnetic resonance imaging and biodegradable macromolecular contrast agents in mice. Pharm Res (2009) 0.91
Stability and biodistribution of a biodegradable macromolecular MRI contrast agent Gd-DTPA cystamine copolymers (GDCC) in rats. Pharm Res (2010) 0.91
Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging. Contrast Media Mol Imaging (2013) 0.91
HPMA copolymer delivery of chemotherapy and photodynamic therapy in ovarian cancer. Adv Exp Med Biol (2003) 0.91
MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model. Pharm Res (2011) 0.90
Noninvasive visualization of in vivo drug delivery of poly(L-glutamic acid) using contrast-enhanced MRI. Mol Pharm (2006) 0.90
Identification of CD21-binding peptides with phage display and investigation of binding properties of HPMA copolymer-peptide conjugates. Bioconjug Chem (2006) 0.90
Modification of Gd-DTPA cystine copolymers with PEG-1000 optimizes pharmacokinetics and tissue retention for magnetic resonance angiography. Magn Reson Med (2007) 0.89
Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol Pharm (2008) 0.89
Synthesis and biological evaluation of disulfide-linked HPMA copolymer-mesochlorin e6 conjugates. Macromol Biosci (2008) 0.89
Single cell molecular recognition of migrating and invading tumor cells using a targeted fluorescent probe to receptor PTPmu. Int J Cancer (2012) 0.89
Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. J Control Release (2005) 0.89
Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates. Pharm Res (2002) 0.89